3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
21
Advanced Breast Cancer
2
Sarcoma, Endometrial Stromal
1
Recurrence
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Endometrial Neoplasms
1
ER+ Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Adenosarcoma of the uterus
1
Interventions
Anastrozole
5
palbociclib
4
abemaciclib
3
Trastuzumab
3
Fulvestrant
3
ribociclib
2
pertuzumab
2
exemestane
2
Tamoxifen
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
AZD9833
2
trastuzumab deruxtecan
1
taxane
1
elacestrant
1
dalpiciclib
1
STX-478
1
RAD1901
1
Metformin
1
Leflunomide
1
Imlunestrant
1
Genotype
1
Body Height
1
Blood Specimen Collection
1
Blood Pressure
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Diseases
×
elacestrant
×
1 year
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled